| Autor: |
Hallek, M, Fischer, K, Fingerle-Rowson, G, Fink, AM, Busch, R, Mayer, J, Hensel, M, Hopfinger, G, Hess, G, von Grünhagen, U, Bergmann, M, Catalano, J, Zinzani, PL, Caligaris-Cappio, F, Seymour, JF, Berrebi, A, Jäger, U, Cazin, B, Trneny, M, Westermann, A, Wendtner, CM, Eichhorst, BF, Staib, P, Bühler, A, Winkler, D, Zenz, T, Böttcher, S, Ritgen, M, Mendila, M, Kneba, M, Döhner, H, Stilgenbauer, S |
| Zdroj: |
The Lancet; October 2010, Vol. 376 Issue: 9747 p1164-1174, 11p |
| Abstrakt: |
On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
